 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.222.969 |
| Chemical and physical data | |
| Formula | C15H10FNO3 |
| Molar mass | 271.247 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Prinaberel ( INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. [1] It is used in scientific research to elucidate the role of the ERβ receptor. [2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. [3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions. [4]
See also
References
- ^ Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology. 144 (10): 4241–9. doi: 10.1210/en.2003-0550. PMID 14500559.
- ^ Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews. 26 (3): 465–78. doi: 10.1210/er.2004-0027. PMID 15857973.
- ^ Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings. 2006/1 (1): 149–61. doi: 10.1007/2789_2006_021. ISBN 978-3-540-49547-5. PMID 17824176.
- ^ "Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Archived from the original on 2016-03-07. Retrieved 2012-05-20.
External links
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.222.969 |
| Chemical and physical data | |
| Formula | C15H10FNO3 |
| Molar mass | 271.247 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Prinaberel ( INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. [1] It is used in scientific research to elucidate the role of the ERβ receptor. [2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. [3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions. [4]
See also
References
- ^ Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology. 144 (10): 4241–9. doi: 10.1210/en.2003-0550. PMID 14500559.
- ^ Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews. 26 (3): 465–78. doi: 10.1210/er.2004-0027. PMID 15857973.
- ^ Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings. 2006/1 (1): 149–61. doi: 10.1007/2789_2006_021. ISBN 978-3-540-49547-5. PMID 17824176.
- ^ "Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Archived from the original on 2016-03-07. Retrieved 2012-05-20.
External links
|
| This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |